Inactive Instrument

Actelion Share Price Xetra

Equities

ACT

CH0010532478

Biotechnology & Medical Research

Chart Actelion

Duration

Period

Style

Latest news about Actelion

Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	31/17/31	RE
Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	19/17/19	RE
Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	19/17/19	RE
Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	09/17/09	RE
Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	09/17/09	RE
Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	09/17/09	RE
Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	22/17/22	RE
Actelion : Johnson & Johnson offers EU concessions over Actelion deal	18/17/18	RE
Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	20/17/20	RE
Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	18/17/18	RE
Actelion : shareholders back R&D spinoff, keep J&J deal on track	05/17/05	RE
Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	31/17/31	RE
Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	23/17/23	RE
Bristol Myers Squibb : Icahn buys Bristol-Myers shares, adding to activist pressure	22/17/22	RE
Actelion : How Sanofi lost out to J&J in $30 billion battle for Actelion	16/17/16	RE

Analyst Recommendations on Actelion

Dollar's post-Fed rally pauses, U.S. stocks end lower	17/16/17	RE
Actelion : raises guidance for third time this year on strong PAH sales	20/16/20	RE

More recommendations

Press releases Actelion

Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	06/20/06	AQ
Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	31/17/31	GL
Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	30/17/30	GL
Actelion : Johnson & Johnson Completes Acquisition of Actelion	16/17/16	GL
Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	16/17/16	PU

More press releases

News in other languages on Actelion

Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR	29/18/29
Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR	29/18/29
Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie	22/18/22
GNW-News: Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	31/17/31
Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	31/17/31

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer